Arthneeti
All Q2 FY27 results →
P

Pfizer Ltd

Q2 FY27Pharmaceuticals & Biotechnology

Pfizer Q2 Results 2026 (FY27): Revenue ₹726.86 Cr, PAT ₹313.25 Cr

Q2 FY27 results statement: what the company reported on revenue, margins and capex.

Price₹3,822
Market cap₹17.5K Cr
P/E22.7
Updated3 Nov 2026
Read2 min read

Pfizer Ltd Q2 FY27 key numbers

Revenue
Revenue from operations for the quarter ended September 30, 2026: ₹726.86 crore.

As stated in Pfizer Ltd's Q2 FY27 results statement · published 3 Nov 2026. Reported figures, not investment advice.

Based on Pfizer Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.

The short version

Revenue from operations for the quarter ended September 30, 2026: ₹726.86 crore (Page 3). EBITDA for the quarter ended September 30, 2026: ₹419.16 crore (calculated as Profit before tax and exceptional items ₹290.77 crore + Depreciation ₹76.96 crore + Finance costs ₹3.35 crore + Other ex.

From Pfizer Ltd's Q2 FY27 earnings-call transcript · updated 3 Nov 2026.

How did Pfizer's revenue grow in the September 2026 quarter?

- Revenue from operations for the quarter ended September 30, 2026: ₹726.86 crore (Page 3). - Corresponding quarter ended September 30, 2025 revenue from operations: ₹642.34 crore (Page 3). - Year-on-year increase in revenue from operations: ₹84.52 crore, approximately 13.17% growth. - Total income for the quarter ended September 30, 2026: ₹774.19 crore, compared to ₹684.19 crore for the corresponding quarter in 2025 (Page 3). The presentation primarily reports financial results without forward-looking revenue or volume guidance.

What happened to Pfizer's margins in Q2 FY27?

See what Pfizer Ltd said on profitability & margins — free account, 30 seconds.

What capex is Pfizer planning?

The only related information is: - Purchase of property, plant, and equipment for the half year ended September 30, 2026, was ₹24.44 crore (Page 5, Cash Flow Statement). - Capital work-in-progress was ₹31.48 crore as of September 30, 2026, up from ₹20.00 crore as of March 31, 2026, indicating ongoing investments in fixed assets (Page 4, Statement of Assets and Liabilities).

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Is Pfizer raising money or cutting debt?

See what Pfizer Ltd said on fundraising & capital structure — free account, 30 seconds.

How big is Pfizer's order book?

See what Pfizer Ltd said on order book & pipeline — free account, 30 seconds.

Pfizer Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹727 Cr, net profit ₹313 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Pfizer's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Remus Pharmaceuticals (Q2 FY27)

    Standalone Revenue (H1 FY27 vs H1 FY26):** ₹62.08 Cr vs ₹46.85 Cr, growth of 32.51% . Key results statement takeaways from Remus Pharmaceuticals Ltd's Q2 FY27 e

  • Amrutanjan Healt (Q2 FY27)

    Q2 FY27 Net Sales:** ₹135.18 Crores, up 14.85% YoY (₹117.70 Crores in Q2 FY26) . Key investor presentation takeaways from Amrutanjan Health Care Ltd's Q2 FY27 i

  • Aarti Drugs (Q2 FY27)

    826.2 Crore, up 27% YoY from Rs. Key investor presentation takeaways from Aarti Drugs Ltd's Q2 FY27 investor presentation — and how it ranks against sector peer

  • Anthem Bioscienc (Q2 FY27)

    Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Pfizer Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Pfizer Ltd Q2 FY27 results?

Revenue from operations for the quarter ended September 30, 2026: ₹726.86 crore (Page 3). EBITDA for the quarter ended September 30, 2026: ₹419.16 crore (calculated as Profit before tax and exceptional items ₹290.77 crore + Depreciation ₹76.96 crore + Finance costs ₹3.35 crore + Other ex.

What is Pfizer Ltd share price analysis?

Pfizer Ltd currently shows a neutral. The stock trades at a P/E of 22.7 with a market cap of ₹17,483 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Pfizer Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.